Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Apricus Biosciences to Present at the 2016 BIO Investor Forum

Apricus Biosciences,Inc.
Posted on: 12 Oct 16

SAN DIEGO, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the 2016 BIO Investor Forum on Wednesday, October 19, 2016, at 8:00 a.m. Pacific Time.  The conference will be held at The Westin St. Francis Hotel in San Francisco, CA.  Mr. Pascoe will provide an update on the Company's strategy and development plans surrounding Vitaros®.

A live audio webcast of the presentation can be accessed via the Investor Relations' section of the Company's website at . Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 30 days following the presentation.

About Apricus Biosciences, Inc .

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus' commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Canada and certain countries in Europe, Latin America and the Middle East, and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus' marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa(TM), its product candidate for the treatment of the circulatory disorder Raynaud's phenomenon.

For further information on Apricus, visit

*Vitaros® is a registered trademark of NexMed International Limited.  Such trademark is registered in certain countries throughout the world and pending registration in the United States.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Apricus Biosciences, Inc. via GlobeNewswire

Last updated on: 13/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.